Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer

Cancer Letters(2024)10.1016/j.canlet.2024.217355Source: DataRank Database

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer is a research paper published in Cancer Letters (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

geo doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.70)OA: greenTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Raghupathy Vengoji ORCID,Rama Krishna Nimmakayala ORCID,Parthasarathy Seshacharyulu ORCID,Balaji Perumalsamy ORCID,Zahraa Wajih Alsafwani ORCID

Live enrichment

PubMed:39603380 PMC:PMC11912633 OpenAlex:https://openalex.org/W4404729454

National Cancer Institute

Grant: R01CA273319

National Cancer Institute

Grant: CA036727

NCI NIH HHS

Grant: P30 CA036727

National Institutes of Health

University of Nebraska Medical Center Fred & Pamela Buffett Cancer Center

FWCI

1.70

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11912633/

publisherhttps://api.elsevier.com/content/article/PII:S030438352400750X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S030438352400750X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.canlet.2024.217355

Fields of Study

Prostate Cancer Treatment and ResearchEpigenetics and DNA MethylationCancer-related gene regulationMedicine

MeSH Terms

DocetaxelAnimalsAntineoplastic AgentsHumansMaleNuclear ProteinsOrganoidsProstatic NeoplasmsTranscription FactorsNeoplastic Stem CellsGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmCell Line, TumorSOXB1 Transcription Factors

Keywords

DocetaxelReprogrammingProstate cancerCancer researchProstateCancerBiologyMedicineInternal medicineGeneticsCellCancer Stem-like CellsCrpcTherapy ResistancePaf1Multicellular Organoid Growth

Sustainable Development Goals

SDG 0: Good health and well-being

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer

FAIR Checklist

Authors (13)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)